Utilization of the Nortropinone Scaffold in the Structure-Guided Design of Potent Inhibitors of Human Cathepsin L and the Chymotrypsin-like Proteases of SARS-CoV-2 and MERS-CoV
ACS Pharmacology & Translational Science · 07.11.2026
DOI: 10.1021/acsptsci.6c00439 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 07.11.2026. Verfasst von Pulini S. Ranasinghe und 18 weiteren Autor:innen. Die Arbeit nennt 83 Literaturangaben. Gefördert von: NIH Office of the Director, Biological and Environmental Research, National Institute on Aging.
Abstract (Originalsprache)
Coronaviruses, including SARS-CoV-2 and MERS-CoV, encode two large polyproteins, pp1a and pp1ab, that are primarily processed by highly conserved 3C-like proteases, yielding an array of structural and nonstructural proteins essential for viral replication. SARS-CoV-2 3CLpro is deemed to be a well-established and validated antiviral target. During cell entry, pathogenic coronaviruses, particularly the SARS-CoV-2 Omicron variants, utilize host cell cathepsins, including cathepsin L (CatL), and the endosomal pathway for successful infection. Furthermore, SARS-CoV-2 infection results in overexpression of CatL, which, in turn, intensifies SARS-CoV-2 infection. Consequently, CatL has emerged as a potential target for the development of COVID-19 therapeutics. We report herein a series of inhibitors that incorporate in their structure a nortropinone scaffold as a design element for probing and exploiting poorly explored regions of chemical space. The inhibitors were found to be noncytotoxic and to potently inhibit CatL and the 3CLpro of MERS-CoV and SARS-CoV-2. The IC50 values of compound 12 against human CatL, MERS-CoV 3CLpro, and SARS-CoV-2 3CLpro were determined to be 0.12 nM, 0.11 μM, and 0.38 μM, respectively. Furthermore, compound 12 was found to inhibit SARS-CoV-2 infection in vitro with an EC50 value of 0.09 ± 0.05 μM and a Safety Index >1100. High-resolution cocrystal structures with SARS-CoV-2 3CLpro and MERS-CoV 3CLpro confirmed the mechanism of action of the compounds, illuminated the molecular determinants associated with binding, and informed the optimization of the inhibitors.
Förderung
- NIH Office of the Director
- Biological and Environmental Research
- National Institute on Aging
- National Institutes of Health
- National Institute of General Medical Sciences
Zitieren
APA
Ranasinghe, P. S., Ilesinghe, I. K. R. S., Dampalla, C. S., Nguyen, H. N., Azmi, Z., Liska, Z., Bourget, J. X., Howard, D. J., Nevonen, D. E., Kim, Y., Battaile, K. P., Cooper, A., Ung, A. R., Thurman, H. A., Gusachenko, E., Johnson, D. K., Lovell, S., Chang, K., & Groutas, W. C. (2026). Utilization of the Nortropinone Scaffold in the Structure-Guided Design of Potent Inhibitors of Human Cathepsin L and the Chymotrypsin-like Proteases of SARS-CoV-2 and MERS-CoV. ACS Pharmacology & Translational Science. https://doi.org/10.1021/acsptsci.6c00439
Vancouver
Ranasinghe PS, Ilesinghe IKRS, Dampalla CS, Nguyen HN, Azmi Z, Liska Z, et al. Utilization of the Nortropinone Scaffold in the Structure-Guided Design of Potent Inhibitors of Human Cathepsin L and the Chymotrypsin-like Proteases of SARS-CoV-2 and MERS-CoV. ACS Pharmacology & Translational Science. 2026. doi:10.1021/acsptsci.6c00439
BibTeX
@article{Ranasinghe2026,
author = {Ranasinghe, Pulini S. and Ilesinghe, I. Kankanamge Ravindu S. and Dampalla, Chamandi S. and Nguyen, Harry Nhat and Azmi, Zeeshan and Liska, Zoie and Bourget, John X. and Howard, Dennis J. and Nevonen, Dustin E. and Kim, Yunjeong and Battaile, Kevin P. and Cooper, Anne and Ung, Adron R. and Thurman, Hayden A. and Gusachenko, Egor and Johnson, David K. and Lovell, Scott and Chang, Kyeong-Ok and Groutas, William C.},
title = {Utilization of the Nortropinone Scaffold in the Structure-Guided Design of Potent Inhibitors of Human Cathepsin L and the Chymotrypsin-like Proteases of SARS-CoV-2 and MERS-CoV},
journal = {ACS Pharmacology & Translational Science},
year = {2026},
doi = {10.1021/acsptsci.6c00439}
}
EUVIMED